Chr. Hansen Holding A/S (CRTSF) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
CRTSF representa a Chr. Hansen Holding A/S, una empresa del sector Basic Materials con un precio de $ (capitalización de mercado 0). Calificado con 48/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.
Ultimo analisis: 17 mar 2026Chr. Hansen Holding A/S (CRTSF) Exposición a Materiales y Productos Básicos
Chr. Hansen Holding A/S is a global bioscience company specializing in natural ingredient solutions for the food, health, and agricultural sectors. With a focus on cultures, enzymes, and probiotics, the company enhances the taste, nutrition, and shelf life of various products, maintaining a strong market presence in diverse industries.
Tesis de Inversión
Chr. Hansen Holding A/S presents a compelling investment case based on its strong market position in the bioscience industry and its focus on natural ingredient solutions. The company's consistent profitability, demonstrated by a 17.0% profit margin and a 54.2% gross margin, highlights its operational efficiency. A key value driver is the increasing demand for natural and sustainable ingredients in the food, health, and agricultural sectors. Growth catalysts include the company's strategic collaboration with UPL Ltd. to develop bio solutions for sustainable agriculture. Potential risks include fluctuations in raw material prices and increasing competition within the specialty chemicals sector. Chr. Hansen's low beta of 0.33 suggests relatively low volatility compared to the overall market.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market capitalization of $10.44 billion, reflecting its significant presence in the bioscience industry.
- P/E ratio of 42.76, indicating investor expectations for future earnings growth.
- Profit margin of 17.0%, showcasing the company's ability to generate profits from its revenue.
- Gross margin of 54.2%, reflecting efficient cost management in the production of its natural ingredient solutions.
- Beta of 0.33, suggesting lower volatility compared to the broader market.
Competidores y Pares
Fortalezas
- Strong market position in bioscience industry.
- Diverse product portfolio of natural ingredient solutions.
- Global presence and distribution network.
- Commitment to innovation and sustainability.
Debilidades
- Reliance on specific industries (food, health, agriculture).
- Exposure to fluctuations in raw material prices.
- Limited dividend yield compared to some competitors.
- OTC market trading may present liquidity challenges.
Catalizadores
- Ongoing: Increasing demand for natural and sustainable ingredients in the food and health industries.
- Ongoing: Strategic collaboration with UPL Ltd. to develop bio solutions for sustainable agriculture.
- Upcoming: Potential expansion into new geographic markets in Asia Pacific and Latin America.
- Ongoing: Growth in the probiotics market driven by increasing consumer awareness of health benefits.
- Upcoming: Development of new and innovative solutions for the food cultures and enzymes market.
Riesgos
- Potential: Fluctuations in raw material prices impacting profitability.
- Potential: Increasing competition from other bioscience companies.
- Potential: Regulatory changes affecting the food and health industries.
- Potential: Economic downturns impacting consumer spending.
- Ongoing: OTC market trading may present liquidity challenges.
Oportunidades de crecimiento
- Expansion in Sustainable Agriculture: Chr. Hansen's collaboration with UPL Ltd. to develop microbial-based bio solutions for sustainable agriculture presents a significant growth opportunity. The global market for bio pesticides is projected to reach $10 billion by 2027, driven by increasing demand for eco-friendly farming practices. This partnership allows Chr. Hansen to leverage its bioscience expertise to capture a share of this rapidly expanding market, offering farmers sustainable alternatives to traditional chemical pesticides.
- Increasing Demand for Probiotics: The global probiotics market is expected to reach $91.09 billion by 2032, growing at a CAGR of 7.4% from 2023. Chr. Hansen is well-positioned to capitalize on this trend through its Health & Nutrition segment, which produces probiotic products for dietary supplements, infant formula, and animal feed. As consumer awareness of the health benefits of probiotics increases, Chr. Hansen can expand its market share by developing innovative probiotic solutions and strengthening its distribution channels.
- Growth in the Food Cultures and Enzymes Market: The market for food cultures and enzymes is driven by the increasing demand for processed and packaged foods with enhanced taste, texture, and shelf life. Chr. Hansen's Food Cultures & Enzymes segment can leverage this trend by developing customized solutions for the dairy, beverage, and bakery industries. The company's expertise in fermentation and enzyme technology provides a competitive advantage in meeting the evolving needs of food manufacturers.
- Geographic Expansion in Emerging Markets: Chr. Hansen has the opportunity to expand its presence in emerging markets, particularly in the Asia Pacific and Latin America regions. These markets are experiencing rapid economic growth and increasing demand for natural ingredient solutions in the food, health, and agricultural sectors. By establishing local partnerships and tailoring its product offerings to meet regional preferences, Chr. Hansen can tap into new revenue streams and diversify its geographic footprint.
- Strategic Acquisitions and Partnerships: Chr. Hansen can pursue strategic acquisitions and partnerships to expand its product portfolio, enhance its technological capabilities, and strengthen its market position. By acquiring companies with complementary technologies or market access, Chr. Hansen can accelerate its growth and innovation efforts. Strategic partnerships with research institutions and industry players can also provide access to new technologies and market opportunities.
Oportunidades
- Expansion in sustainable agriculture and bio solutions.
- Increasing demand for probiotics and natural ingredients.
- Geographic expansion in emerging markets.
- Strategic acquisitions and partnerships.
Amenazas
- Increasing competition from other bioscience companies.
- Regulatory changes affecting the food and health industries.
- Economic downturns impacting consumer spending.
- Potential disruptions in supply chains.
Ventajas competitivas
- Proprietary technology in fermentation and enzyme production.
- Strong brand reputation for quality and innovation.
- Extensive portfolio of natural ingredient solutions.
- Global distribution network and customer relationships.
Acerca de CRTSF
Founded in 1843 and headquartered in Hørsholm, Denmark, Chr. Hansen Holding A/S has evolved into a leading bioscience company with a global footprint. The company develops and provides natural ingredient solutions to the food, nutritional, pharmaceutical, and agricultural industries. Chr. Hansen operates through two primary segments: Food Cultures & Enzymes, and Health & Nutrition. The Food Cultures & Enzymes segment focuses on producing and selling cultures, enzymes, and probiotic products that enhance the taste, flavor, texture, shelf life, nutritional value, and health benefits of food products, particularly in the dairy industry. The Health & Nutrition segment offers solutions for dietary supplements, over-the-counter pharmaceuticals, infant formula, animal feed, and plant protection. Chr. Hansen's commitment to innovation and sustainability is underscored by its strategic collaboration with UPL Ltd. to develop and commercialize microbial-based bio solutions for sustainable agriculture. With a long history of pioneering bioscience, Chr. Hansen continues to expand its offerings and global reach, serving a diverse range of customers across Europe, the Middle East, Africa, North America, Latin America, and the Asia Pacific region.
Qué hacen
- Develops natural ingredient solutions for the food industry.
- Produces cultures and enzymes for dairy products.
- Offers probiotic products for dietary supplements.
- Provides solutions for the pharmaceutical industry.
- Develops products for animal feed and plant protection.
- Collaborates on microbial-based bio solutions for agriculture.
- Enhances the taste, texture, and shelf life of food products.
Modelo de Negocio
- Develops and manufactures natural ingredients.
- Sells products directly to food, health, and agricultural companies.
- Generates revenue through product sales and licensing agreements.
- Invests in research and development to innovate new solutions.
Contexto de la Industria
Chr. Hansen Holding A/S operates within the specialty chemicals industry, which is characterized by innovation, sustainability, and increasing demand for natural ingredients. The global market for specialty chemicals is driven by the food, health, and agricultural sectors, with a growing emphasis on bio-based solutions. Chr. Hansen competes with companies like ACHHY (Ajinomoto Co., Inc.), ASGLF (Associated British Foods plc), AWCMY (Archer-Daniels-Midland Company), BOLIF (Koninklijke DSM N.V.), and HMTLY (Hormel Foods Corporation), each vying for market share through unique product offerings and strategic partnerships. The industry is witnessing a shift towards sustainable practices and consumer preferences for healthier, natural products, positioning Chr. Hansen favorably due to its focus on bioscience and natural ingredient solutions.
Clientes Clave
- Food manufacturers in the dairy, beverage, and bakery industries.
- Dietary supplement companies producing probiotic products.
- Pharmaceutical companies developing over-the-counter medications.
- Agricultural companies seeking sustainable plant protection solutions.
Finanzas
Gráfico e información
Precio de la acción de Chr. Hansen Holding A/S (CRTSF): Price data unavailable
Últimas noticias
-
Stocks That Hit 52-Week Lows On Friday
· 28 feb 2020
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para CRTSF.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para CRTSF.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de CRTSF en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Mauricio Graber
CEO
Mauricio Graber serves as the CEO of Chr. Hansen Holding A/S. His career spans various leadership roles in the food and beverage industry. Before joining Chr. Hansen, he held significant positions at Nestlé, including Regional Business Head for the Infant Nutrition division in Latin America and CEO of Nestlé Mexico. Graber brings extensive experience in strategy, operations, and market development to his role at Chr. Hansen.
Historial: Under Mauricio Graber's leadership, Chr. Hansen has focused on strengthening its position as a leading bioscience company and expanding its presence in sustainable agriculture. He has overseen strategic collaborations, such as the partnership with UPL Ltd., to develop innovative bio solutions. Graber has also emphasized the importance of sustainability and innovation in driving long-term growth for the company.
Información del mercado OTC de CRTSF
The OTC Other tier represents the lowest tier of the OTC market, indicating that Chr. Hansen Holding A/S (CRTSF) may have limited reporting requirements or may not meet the listing standards of higher tiers like OTCQX or OTCQB. Unlike stocks listed on major exchanges such as the NYSE or NASDAQ, OTC Other stocks often have less stringent financial and regulatory oversight, which can result in higher risks for investors due to potential information asymmetry and reduced transparency.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure and transparency.
- Potential for lower liquidity and higher price volatility.
- Increased risk of fraud or manipulation.
- Lack of regulatory oversight compared to major exchanges.
- Information asymmetry and difficulty in conducting due diligence.
- Verify the company's financial statements and reporting history.
- Assess the company's management team and corporate governance practices.
- Review the company's business model and competitive landscape.
- Analyze the company's risk factors and potential liabilities.
- Evaluate the company's liquidity and trading volume on the OTC market.
- Consult with a financial advisor to assess the suitability of the investment.
- Confirm the company's legal and regulatory compliance.
- Established history as a bioscience company since 1843.
- Global presence and operations in multiple regions.
- Strategic collaborations with reputable companies like UPL Ltd.
- Focus on innovation and sustainability.
- Experienced management team led by CEO Mauricio Graber.
CRTSF Preguntas Frecuentes sobre Acciones de Basic Materials
¿Cuáles son los factores clave para evaluar CRTSF?
Chr. Hansen Holding A/S (CRTSF) actualmente tiene una puntuación IA de 48/100, indicando puntuación baja. Fortaleza clave: Strong market position in bioscience industry.. Riesgo principal a monitorear: Potential: Fluctuations in raw material prices impacting profitability.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de CRTSF?
CRTSF actualmente puntúa 48/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de CRTSF?
Los precios de CRTSF se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre CRTSF?
La cobertura de analistas para CRTSF incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en CRTSF?
Las categorías de riesgo para CRTSF incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Fluctuations in raw material prices impacting profitability.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de CRTSF?
La relación P/E para CRTSF compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está CRTSF sobrevalorada o infravalorada?
Determinar si Chr. Hansen Holding A/S (CRTSF) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de CRTSF?
Chr. Hansen Holding A/S (CRTSF) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Information is based on available data and may be subject to change.
- OTC market data may be limited or less reliable than exchange-listed data.